Stephanie L. Graff, MD, FACP

Articles

Dr. Graff on Future Research With Immunotherapy in Breast Cancer

June 15th 2020

Stephanie L. Graff, MD, discusses future research with immunotherapy in breast cancer.

Dr. Graff on the FDA Approval of Sacituzumab Govitecan in TNBC

April 22nd 2020

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC).

Dr. Graff on Genomic Risk Prediction in HR+/HER2- Breast Cancer

April 11th 2020

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr. Graff on Extended Adjuvant Therapy in Early-Stage HR+ Breast Cancer

January 15th 2020

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.

Stephanie Graff, MD: Information Is Power for Patients With Breast Cancer

January 1st 2020

Stephanie L. Graff, MD, shared the importance of personalizing care for her patients with breast cancer, how she balances her professional and personal life, using the optimal voice on social media, and her vision for the future of breast cancer treatment.

Dr. Graff on Current Treatments in ESR1-Mutant Breast Cancer

September 25th 2019

Dr. Graff Underscores Unmet Needs in ESR1-Mutated Breast Cancer

September 9th 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses some unmet needs of patients with ESR1-mutated metastatic breast cancer.

Dr. Graff Discusses Optimal Dosing of Tamoxifen in Breast Cancer

February 26th 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses patient factors used to consider optimal treatment duration of tamoxifen in patients with breast cancer.

Dr. Graff on Tamoxifen De-Escalation in Breast Cancer

February 1st 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the use of tamoxifen in the treatment of patients with breast cancer.

Dr. Graff on Novel Therapies in Metastatic Breast Cancer

September 21st 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.

Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

July 24th 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.